Redeye presents its preview for Devyser’s Q4 2024 report, due on February 13.
Redeye’s view on the Q4 report. The organic growth was weak, with large swings in the development in...
Sales and EBITA in line, c. 6% organic growth y-o-y Better customer intake, +1,900 q-o-q (ABG +1,000...
Redeye comments on Alligator Bioscience's end of phase II meeting with the American regulatory autho...
Redeye returns following Elicera's Q4 report and recent news in the company.
Redeye reinforces its positive view on Transtema following a Q4 report showing strong development in...
Sales +36% and EBIT +82% vs. ABGSCe Expect cons. to raise '25e-'26e sales by ~15% Overall a strong b...
Fiskars’ net sales continued the decreasing trend y/y in both Business Areas due to low consumer con...
Binero Group acquires 100% of IT Partner i Tromsø AS (Serit Tromsø).
After a period of steady increase in both European Idefirix sales and patient usage, Hansa records a...
Redeye updates on Better Collective ahead of Q4-results (due February 19) where we expect a slight s...
Redeye provides an in-depth review of Episurf Medical’s Q4 report and events during and after the qu...
Redeye initiates coverage of NextCell Pharma, a clinical-stage biotech company developing a cell the...
Q4 with meagre 5% organic growth and EBITDA 2% below But quite a few positives in the underlying ope...
Q4 report on Thursday, 13 February Centennial Flats the largest Q4 contributor Expecting updates on ...
